Treatment with the investigational oral treatment for relapsing-remitting multiple sclerosis, dimethyl fumarate (aka BG-12), yielded significant reductions in the annualized relapse rate and risk of relapse.

After a 24-week cessation of natalizumab treatment, a high rate of MRI and clinical disease activity recurs in patients with multiple sclerosis.

The monoclonal antibody, alemtuzumab, significantly reducesthe number of relapses and the accumulation of disability in patients with relapsing-remitting multiple sclerosis who had relapsed on prior therapy.

The once-daily oral MS drug, fingolimod, slows brain volume loss in patients with MS, regardless of inflammatory activity.

The once-daily oral MS drug, fingolimod, reduces annualized relapse rates in patients who achieved unsatisfactory responses when treated with other disease-modifying therapies or who had been treated for an extended period of time.

Treatment with the investigational oral drug for RRMS, dimethylfumarate (aka BG-12), yielded significant reductions in inflammatory disease activity using MRI outcomes.

Rats with spinal cord injury are able to regain locomotion after electrochemical treatment and encouragement of supraspinally mediated movements, in a cortical-dependent manner.

For patients with type 2 diabetes, depression is associated with an increased risk of all-cause mortality, regardless of previous cardiovascular disease.

In this podcast, Dr. Church reviews the developments of new treatments for HIV.

Many psoriasis patients have the same gene variants as people who are not significantly affected by an HIV-1 infection.